A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Recruiting at 38 trial locations

Overseen By There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Eli Lilly and Company

Disqualifiers: Diabetes, Obesity surgery, Renal impairment, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 36 weeks

272 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called LY3502970 to see if it can help people who are overweight or have obesity lose weight.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you have a stable condition like Major Depressive Disorder or generalized anxiety disorder, you may be included if you are not on excluded medications.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-5615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)

Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]

Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LY3502970 or placebo with dose escalation until a maintenance dose is reached, administered orally once daily for 36 weeks

36 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• LY3502970
• Placebo

Participant Groups

Group I: 45 mg-2 LY3502970 Experimental Treatment 1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

Group II: 45 mg-1 LY3502970 Experimental Treatment 1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

Group III: 36 mg-2 LY3502970 Experimental Treatment 1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Group IV: 36 mg-1 LY3502970 Experimental Treatment 1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Group V: 24 mg LY3502970 Experimental Treatment 1 Intervention

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

Group VI: 12 milligram (mg) LY3502970 Experimental Treatment 1 Intervention

Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

Group VII: Placebo Placebo Group 1 Intervention

Participants received placebo administered orally once daily until 36 weeks.

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University